EUVIMEDEUVIMED entdecken
Crossref

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population

Antonio De Vincentis iD, Federica Tavaglione, Shinichi Namba, Masahiro Kanai, Yukinori Okada, Yoichiro Kamatani, Samantha Maurotti, Claudio Pedone, Raffaele Antonelli Incalzi, Luca Valenti iD, Stefano Romeo iD, Umberto Vespasiani-Gentilucci iD

Alimentary Pharmacology & Therapeutics · 2024

DOI: 10.1111/apt.17953 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Antonio De Vincentis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Unit, Department of Internal Medicine and Geriatrics, Campus Bio-Medico University, Rome, Italy. Hauptthemen laut MEDLINE: Fatty Liver, Mass Screening. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Swedish Research Council, Swedish state under the agreement between the Swedish government and the county councils (ALF Agreement), Swedish Diabetes Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The European Association for the Study of the Liver introduced a clinical pathway (EASL CP) for screening significant/advanced fibrosis in people at risk of steatotic liver disease (SLD). We assessed the performance of the first‐step FIB4 EASL CP in the general population across different SLD risk groups (MASLD, Met‐ALD and ALD) and various age classes.

Methods

We analysed a total of 3372 individuals at risk of SLD from the 2017–2018 National Health and Nutrition Examination Survey (NHANES17‐18), projected to 152.3 million U.S. adults, 300,329 from the UK Biobank (UKBB) and 57,644 from the Biobank Japan (BBJ). We assessed liver stiffness measurement (LSM) ≥8 kPa and liver‐related events occurring within 3 and 10 years (3/10 year‐LREs) as outcomes. We defined MASLD, MetALD, and ALD according to recent international recommendations.

Results

FIB4 sensitivity for LSM ≥ 8 kPa was low (27.7%), but it ranged approximately 80%‐90% for 3‐year LREs. Using FIB4, 22%–57% of subjects across the three cohorts were identified as candidates for vibration‐controlled transient elastography (VCTE), which was mostly avoidable (positive predictive value of FIB4 ≥ 1.3 for LSM ≥ 8 kPa ranging 9.5%–13% across different SLD categories). Sensitivity for LSM ≥ 8 kPa and LREs increased with increasing alcohol intake (ALD>MetALD>MASLD) and age classes. For individuals aged ≥65 years, using the recommended age‐adjusted FIB4 cut‐off (≥2) substantially reduced sensitivity for LSM ≥ 8 kPa and LREs.

Conclusions

The first‐step FIB4 EASL CP is poorly accurate and feasible for individuals at risk of SLD in the general population. It is crucial to enhance the screening strategy with a first‐step approach able to reduce unnecessary VCTEs and optimise their yield.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverMass ScreeningAdultAgedFemaleHumansMaleMiddle AgedElasticity Imaging TechniquesJapanLiver CirrhosisNon-alcoholic Fatty Liver DiseaseNutrition SurveysRisk AssessmentRisk FactorsSensitivity and SpecificityUnited States

Stichwörter der Autor:innen

ALDFIB4MASLDMetALDliver stiffness measurementliver‐related eventssteatotic liver disease

Autor:innen und Institutionen

  • Internal Medicine Unit, Department of Internal Medicine and Geriatrics, Campus Bio-Medico University, Rome, Italy.
  • Clinical Medicine and Hepatology Unit, Department of Internal Medicine and Geriatrics, Campus Bio-Medico University, Rome, Italy.
  • Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Antonio De Vincentis, Luca Valenti, Stefano Romeo, Umberto Vespasiani-Gentilucci

Förderung

  • Swedish Research Council
  • Swedish state under the agreement between the Swedish government and the county councils (ALF Agreement)
  • Swedish Diabetes Foundation
  • Swedish Heart-Lung Foundation
  • Knut and Alice Wallenberg Foundation
  • Astra Zeneca Agreement for Research
  • Swedish Foundation for Strategic Research
  • Novo Nordisk Project Grants in Endocrinology & Metabolism - Nordic Region 2020

Zitieren

APA

De Vincentis, A., Tavaglione, F., Namba, S., Kanai, M., Okada, Y., Kamatani, Y., Maurotti, S., Pedone, C., Antonelli Incalzi, R., Valenti, L., Romeo, S., & Vespasiani-Gentilucci, U. (2024). Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17953

Vancouver

De Vincentis A, Tavaglione F, Namba S, Kanai M, Okada Y, Kamatani Y, et al. Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17953

BibTeX
@article{DeVincentis2024,
  author = {De Vincentis, Antonio and Tavaglione, Federica and Namba, Shinichi and Kanai, Masahiro and Okada, Yukinori and Kamatani, Yoichiro and Maurotti, Samantha and Pedone, Claudio and Antonelli Incalzi, Raffaele and Valenti, Luca and Romeo, Stefano and Vespasiani-Gentilucci, Umberto},
  title = {Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1111/apt.17953}
}
Kostenlos starten →